ENLV

MKT CAP:$22M

Enlivex Therapeutics Ltd.

Market Cap

$22M

Healthcare·Biotechnology·🇮🇱 Israel·NASDAQ

Healthcare·Biotechnology·🇮🇱·NASDAQ

Stock Price

$0.91+$0.15 (+20.11%)

Apr 23, 2026

Company Details

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinic...

CEO

Oren Hershkovitz

IPO Date

Jul 31, 2014

Website

www.enlivex.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

$1.2B

EPS (Diluted)

$25.46

Free Cash Flow

-$11M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

0.0x

Earnings Reports

FY 2025

Mar 25, 2026

$0EPS $25.48

Q4 2025

Mar 25, 2026

$0EPS $25.79

Q3 2025

Nov 14, 2025

$0EPS -$0.09

Q2 2025

Aug 29, 2025

$0EPS -$0.08

Q1 2025

May 30, 2025

$0EPS -$0.16

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	-$188.0K	-$6M
Q2 22	$0	-$176.0K	-$6M
Q3 22	$0	-$192.0K	-$6M
Q4 22	$0	-$221.0K	-$8M
Q1 23	$0	-$209.0K	-$7M
Q2 23	$0	-$212.0K	-$7M
Q3 23	$0	-$214.0K	-$6M
Q4 23	$0	-$200.0K	-$6M
Q1 24	$0	-$188.0K	-$4M
Q2 24	$0	-$160.0K	-$3M
Q3 24	$0	-$161.0K	-$3M
Q4 24	$0	-$36.0K	-$6M
Q1 25	$0	-$90.0K	-$4M
Q2 25	$0	-$85.0K	-$3M
Q3 25	$0	-$81.0K	-$3M
Q4 25	$0	-$76.0K	-$6M

Valuation

Quarter	P/S	P/E
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	0.0x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$3M	-$4M
Q2 22	-$9M	-$13M
Q3 22	-$7M	-$8M
Q4 22	-$5M	-$7M
Q1 23	-$6M	-$6M
Q2 23	-$7M	-$7M
Q3 23	-$5M	-$5M
Q4 23	-$5M	-$5M
Q1 24	-$5M	-$5M
Q2 24	-$2M	-$2M
Q3 24	-$3M	-$3M
Q4 24	-$4M	-$4M
Q1 25	-$5M	-$5M
Q2 25	-$1M	-$1M
Q3 25	-$2M	-$2M
Q4 25	-$3M	-$3M

Capital Expenditures

Quarter	CapEx
Q1 22	$952.0K
Q2 22	$3M
Q3 22	$1M
Q4 22	$3M
Q1 23	$162.0K
Q2 23	$38.0K
Q3 23	$29.0K
Q4 23	$5.9K
Q1 24	$43.0K
Q2 24	$16.0K
Q3 24	$9.0K
Q4 24	$35.0K
Q1 25	$32.0K
Q2 25	$7.0K
Q3 25	$23.6K
Q4 25	$9.4K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+68.4%
Q2 22	—	+54.2%
Q3 22	—	+46.9%
Q4 22	—	+0.4%
Q1 23	—	+5.9%
Q2 23	—	+13.3%
Q3 23	—	-0.9%
Q4 23	—	-22.4%
Q1 24	—	-41.8%
Q2 24	—	-55.1%
Q3 24	—	-44.6%
Q4 24	—	-7.5%
Q1 25	—	-10.6%
Q2 25	—	+3.1%
Q3 25	—	-18.0%
Q4 25	—	+4.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$788.0K	—
Q2 22	$697.0K	—
Q3 22	$470.0K	—
Q4 22	$757.0K	—
Q1 23	$633.0K	—
Q2 23	$511.0K	—
Q3 23	$407.0K	—
Q4 23	$400.0K	—
Q1 24	$383.0K	—
Q2 24	$388.0K	—
Q3 24	$377.0K	—
Q4 24	$0	—
Q1 25	$293.0K	—
Q2 25	$295.0K	—
Q3 25	$0	—
Q4 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$5M	$2M	—
Q2 22	$4M	$2M	—
Q3 22	$4M	$1M	—
Q4 22	$6M	$2M	—
Q1 23	$5M	$2M	—
Q2 23	$5M	$2M	—
Q3 23	$4M	$1M	—
Q4 23	$4M	$733.0K	—
Q1 24	$3M	$1M	—
Q2 24	$2M	$987.0K	—
Q3 24	$2M	$771.0K	—
Q4 24	$3M	$2M	—
Q1 25	$3M	$954.0K	—
Q2 25	$2M	$937.0K	—
Q3 25	$1M	—	$992.0K
Q4 25	$3M	—	$3M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$68M	$10M	$78M
Q2 22	$20M	$42M	$62M
Q3 22	$39M	$0	$39M
Q4 22	$48M	$299.0K	$48M
Q1 23	$13M	$23M	$36M
Q2 23	$3M	$25M	$29M
Q3 23	$2M	$29M	$30M
Q4 23	$926.0K	$27M	$27M
Q1 24	$2M	$22M	$24M
Q2 24	$4M	$22M	$26M
Q3 24	$3M	$22M	$25M
Q4 24	$3M	$20M	$23M
Q1 25	$2M	$18M	$21M
Q2 25	$2M	$18M	$20M
Q3 25	$4M	$14M	$18M
Q4 25	$2M	$4M	$6M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	18M	+0.3%	+11.5%
Q2 22	18M	+0.0%	+0.4%
Q3 22	18M	+0.1%	+0.4%
Q4 22	18M	+0.2%	+0.6%
Q1 23	19M	+0.5%	+0.8%
Q2 23	19M	+0.4%	+1.1%
Q3 23	19M	+0.1%	+1.1%
Q4 23	19M	+0.0%	+1.0%
Q1 24	19M	+0.7%	+1.1%
Q2 24	20M	+4.4%	+5.2%
Q3 24	21M	+8.9%	+14.4%
Q4 24	22M	+2.9%	+17.7%
Q1 25	22M	0.0%	+16.9%
Q2 25	24M	+9.0%	+22.1%
Q3 25	24M	+0.8%	+13.0%
Q4 25	48M	+100.4%	+120.1%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	71
Q2 22	$0	71
Q3 22	$0	71
Q4 22	$0	77
Q1 23	$0	77
Q2 23	$0	77
Q3 23	$0	77
Q4 23	$0	49
Q1 24	$0	49
Q2 24	$0	49
Q3 24	$0	49
Q4 24	$0	36
Q1 25	$0	36
Q2 25	$0	36
Q3 25	$0	36
Q4 25	$0	10K

Revenue / Employee